Cargando…

Clinical Significance of Circulating Cell-Free DNA Detection in Multiple Myeloma: A Meta-Analysis

Circulating cell-free DNA (cfDNA) detection, a non-invasive method, appears promising for genetic analyses as well as quantitative assessment of tumor burden in patients with cancer. Although the analysis of cfDNA for clinical prognosis and monitoring disease burden in multiple myeloma (MM) has been...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ye, Xueshi, Li, Wanli, Zhang, Lifei, Yu, Junyao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8894433/ https://www.ncbi.nlm.nih.gov/pubmed/35252019 http://dx.doi.org/10.3389/fonc.2022.852573

Ejemplares similares

Cytotoxic T Cell Responses Induced by CS1/CRT Fusion DNA Vaccine in a Human Plasmacytoma Model
por: Ye, Xueshi, et al.
Publicado: (2020)

High-dose methotrexate-based regimens and post-remission consolidation for treatment of newly diagnosed primary CNS lymphoma: meta-analysis of clinical trials
por: Yu, Junyao, et al.
Publicado: (2021)

The prognostic significance of circulating plasma cells in newly diagnosed multiple myeloma patients
por: Yao, Weiqin, et al.
Publicado: (2023)

Maintenance Therapy with Immunomodulatory Drugs after Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials
por: Ye, Xueshi, et al.
Publicado: (2013)

Circulating miRNAs as Auxiliary Diagnostic Biomarkers for Multiple Myeloma: A Systematic Review, Meta-Analysis, and Recommendations
por: Xiang, Yunhui, et al.
Publicado: (2021)

Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis
por: Yu, Dandan, et al.
Publicado: (2019)

Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis
por: Tan, Xiangyu, et al.
Publicado: (2021)

Assessment of Molecular Residual Disease Using Circulating Tumor DNA to Identify Multiple Myeloma Patients at High Risk of Relapse
por: Dhakal, Binod, et al.
Publicado: (2022)

Detection and utility of cell-free and circulating tumour DNA in bone and soft-tissue sarcomas
por: Tsoi, Kim M., et al.
Publicado: (2021)

Precision Oncology: Artificial Intelligence and DNA Methylation Analysis of Circulating Cell-Free DNA for Lung Cancer Detection
por: Bahado-Singh, Ray, et al.
Publicado: (2022)

High-risk multiple myeloma predicted by circulating plasma cells and its genetic characteristics
por: Xia, Yuan, et al.
Publicado: (2023)

Circulating Cell-Free DNA-Based Detection of Tumor Suppressor Gene Copy Number Loss and Its Clinical Implication in Metastatic Prostate Cancer
por: Dong, Xiaoxi, et al.
Publicado: (2021)

Clinical Significance of Hotspot Mutation Analysis of Urinary Cell-Free DNA in Urothelial Bladder Cancer
por: Hayashi, Yujiro, et al.
Publicado: (2020)

Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
por: Muylaert, Catharina, et al.
Publicado: (2022)

Minimal Residual Disease Assessment Within the Bone Marrow of Multiple Myeloma: A Review of Caveats, Clinical Significance and Future Perspectives
por: Romano, Alessandra, et al.
Publicado: (2019)

Are the Derived Indexes of Peripheral Whole Blood Cell Counts (NLR, PLR, LMR/MLR) Clinically Significant Prognostic Biomarkers in Multiple Myeloma? A Systematic Review And Meta-Analysis
por: Zhang, Xinwen, et al.
Publicado: (2021)

Identification of Somatic Mutations in Papanicolaou Smear DNA and Plasma Circulating Cell-Free DNA for Detection of Endometrial and Epithelial Ovarian Cancers: A Pilot Study
por: Jiang, Xuan, et al.
Publicado: (2020)

Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma
por: Manier, S., et al.
Publicado: (2018)

The level and integrity of plasma circulating cell-free DNA in patients with primary multiple myeloma
por: Shen, Qian, et al.
Publicado: (2022)

Circulating Plasma Cells as a Biomarker to Predict Newly Diagnosed Multiple Myeloma Prognosis: Developing Nomogram Prognostic Models
por: Cheng, Qianwen, et al.
Publicado: (2021)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Therapeutic Advancements in Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2014)

Standardized Minimal Residual Disease Detection by Next-Generation Sequencing in Multiple Myeloma
por: Yao, Qiumei, et al.
Publicado: (2019)

KRAS Mutant Allele Fraction in Circulating Cell-Free DNA Correlates With Clinical Stage in Pancreatic Cancer Patients
por: Wang, Zhe-Ying, et al.
Publicado: (2019)

Prognostic Significance of the Stage at Which an MRD-Negative Status Is Achieved for Patients With Multiple Myeloma Who Received ASCT
por: Sun, Qian, et al.
Publicado: (2022)

The independent adverse prognostic significance of 1q21 gain/amplification in newly diagnosed multiple myeloma patients
por: You, Hongying, et al.
Publicado: (2022)

Effect modification in network meta-analyses for relapsed/refractory multiple myeloma: systematic review and meta-analysis
por: Rose, Christopher James, et al.
Publicado: (2023)

Targeting Ongoing DNA Damage in Multiple Myeloma: Effects of DNA Damage Response Inhibitors on Plasma Cell Survival
por: Herrero, Ana Belén, et al.
Publicado: (2017)

Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells
por: Mack, Elisabeth K. M., et al.
Publicado: (2022)

Monitoring multiple myeloma by next-generation sequencing of V(D)J rearrangements from circulating myeloma cells and cell-free myeloma DNA
por: Oberle, Anna, et al.
Publicado: (2017)

The Potential Clinical Utility of Circulating Tumor DNA in Esophageal Adenocarcinoma: From Early Detection to Therapy
por: Kosovec, Juliann E., et al.
Publicado: (2018)

Can urine studies be replaced by serum free light chains measurements to assign responses in multiple myeloma patients?
por: Cárdenas, Maria Cruz, et al.
Publicado: (2022)

The Clinical Characteristics of Multiple Myeloma in the Acute Care Setting: Case Presentation and Clinical Recommendations
por: Zetter, Daniel R, et al.
Publicado: (2020)

Editorial: Molecular Mechanisms of Multiple Myeloma
por: Gozzetti, Alessandro, et al.
Publicado: (2022)

Network Meta-Analysis of Once Weekly Selinexor-Bortezomib-Dexamethasone in Previously Treated Multiple Myeloma
por: Dolph, Michael, et al.
Publicado: (2021)

Treatment of Lenalidomide Exposed or Refractory Multiple Myeloma: Network Meta-Analysis of Lenalidomide-Sparing Regimens
por: Botta, Cirino, et al.
Publicado: (2021)

Telomere Length of Circulating Cell-Free DNA and Gastric Cancer in a Chinese Population at High-Risk
por: Shi, Yu, et al.
Publicado: (2019)

Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma
por: Oliva, Stefania, et al.
Publicado: (2020)

Next-Generation Sequencing for Clinical Management of Multiple Myeloma: Ready for Prime Time?
por: Bolli, Niccolo, et al.
Publicado: (2020)

Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma
por: Zhang, Liangxuan, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l77t3pqe52te3oobphhkcg11na